Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Acrivon Therapeutics, Inc. 0.00%
Acrivon Therapeutics, Inc. ACRV | 8.05 | 0.00% |
Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:
ACRV) from Buy to Neutral.